821P Safety and efficacy of infrequent tebentafusp treatment omissions in patients with metastatic uveal melanoma

Abstract

Tebentafusp (tebe) (gp100×CD3) is the first TCR bispecific protein approved for treatment of a solid tumor (metastatic uveal melanoma, mUM). The IMCgp100-202 trial (NCT03070392) in untreated mUM demonstrated improved overall survival, HR=0.51. The most frequent treatment-related AEs (TRAEs), cytokine release syndrome (CRS) and rash, were consistent with mechanism of action and were most common in the first 3 weeks (wks). Once the target dose has been achieved after the first 3 intrapatient escalation doses, tebe is administered as outpatient.